Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Orissa, India.
Department of Pharmacology, AIIMS, Bibinagar, Hyderabad, India.
J Am Nutr Assoc. 2024 Feb;43(2):147-156. doi: 10.1080/27697061.2023.2233008. Epub 2023 Jul 17.
(Fenugreek) is an extensively researched phytotherapeutic for the management of Type 2 diabetes without any associated side effects. The major anti-diabetic bioactive constituents present in the plant are furostanolic saponins, which are more abundantly available in the seed of the plant. However, the bioavailability of these components depends on the method of extraction and hence formulation of the phytotherapeutic constitutes a critical step for its success.
The present study reports the efficacy of a novel, patented fenugreek seed extract, Fenfuro®, containing significant amount of furostanolic saponins, in an open-labelled, two-armed, single centric study on a group of 204 patients with Type 2 diabetes mellitus over a period of twelve consecutive weeks.
Administration of Fenfuro in the dosage of 500 mg twice daily along with metformin and/or sulfonylurea-based prescribed antidiabetic drug resulted in a reduction of post-prandial glucose by more than 33% along with significant reduction in fasting glucose, both of which were greater than what resulted for the patient group receiving only Metformin and/or Sulfonylurea therapy. Fenfuro also resulted in reduction in mean baseline HOMA index from 4.27 to 3.765, indicating restoration of insulin sensitivity which was also supported by a significant decrease in serum insulin levels by >10% as well as slight reduction in the levels of C-peptide. However, in the case of the Metformin and/or Sulfonylurea group, insulin levels were found to increase by more than 14%, which clearly indicated that drug-induced suppression of glucose levels instead of restoration of glucose homeostasis. Administration of the formulation was also found to be free from any adverse side effects as there were no changes in hematological profile, liver function and renal function.
The study demonstrated the promising potential of this novel phytotherapeutic, Fenfuro, in long-term holistic management of type-2 diabetes.
（葫芦巴）是一种广泛研究的植物疗法，可用于治疗 2 型糖尿病，且无任何相关副作用。植物中存在的主要抗糖尿病生物活性成分是呋甾烷皂苷，其在植物种子中含量更为丰富。然而，这些成分的生物利用度取决于提取方法，因此植物疗法的配方是其成功的关键步骤。
本研究报告了一种新型专利葫芦巴种子提取物 Fenfuro®的疗效，该提取物含有大量呋甾烷皂苷，在一项为期 12 周的 204 例 2 型糖尿病患者的开放性、双臂、单中心研究中进行了评估。
Fenfuro 以 500mg 每日两次的剂量与二甲双胍和/或磺酰脲类处方抗糖尿病药物联合使用，可使餐后血糖降低 33%以上，同时空腹血糖显著降低，这两项指标的改善均优于仅接受二甲双胍和/或磺酰脲类药物治疗的患者组。Fenfuro 还使平均基线 HOMA 指数从 4.27 降低至 3.765，表明胰岛素敏感性得到恢复，这也得到了血清胰岛素水平降低 10%以上以及 C 肽水平略有降低的支持。然而，在二甲双胍和/或磺酰脲类药物组中，胰岛素水平发现增加了 14%以上，这清楚地表明药物诱导的血糖水平降低而不是葡萄糖内稳态的恢复。该配方的给药也被发现没有任何不良反应，因为血液学特征、肝功能和肾功能均无变化。
该研究表明，这种新型植物疗法 Fenfuro 在 2 型糖尿病的长期整体管理中具有很大的潜力。
Zotero 插件